1. Home
  2. IMCR vs TSLX Comparison

IMCR vs TSLX Comparison

Compare IMCR & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • TSLX
  • Stock Information
  • Founded
  • IMCR 2008
  • TSLX 2010
  • Country
  • IMCR United Kingdom
  • TSLX United States
  • Employees
  • IMCR N/A
  • TSLX N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • TSLX Investment Managers
  • Sector
  • IMCR Health Care
  • TSLX Finance
  • Exchange
  • IMCR Nasdaq
  • TSLX Nasdaq
  • Market Cap
  • IMCR 1.5B
  • TSLX 2.1B
  • IPO Year
  • IMCR 2021
  • TSLX 2014
  • Fundamental
  • Price
  • IMCR $33.02
  • TSLX $24.37
  • Analyst Decision
  • IMCR Buy
  • TSLX Strong Buy
  • Analyst Count
  • IMCR 10
  • TSLX 8
  • Target Price
  • IMCR $58.13
  • TSLX $22.69
  • AVG Volume (30 Days)
  • IMCR 444.9K
  • TSLX 598.4K
  • Earning Date
  • IMCR 08-07-2025
  • TSLX 07-30-2025
  • Dividend Yield
  • IMCR N/A
  • TSLX 8.54%
  • EPS Growth
  • IMCR N/A
  • TSLX N/A
  • EPS
  • IMCR N/A
  • TSLX 1.89
  • Revenue
  • IMCR $333,581,000.00
  • TSLX $481,092,000.00
  • Revenue This Year
  • IMCR $26.82
  • TSLX N/A
  • Revenue Next Year
  • IMCR $8.15
  • TSLX N/A
  • P/E Ratio
  • IMCR N/A
  • TSLX $12.90
  • Revenue Growth
  • IMCR 25.75
  • TSLX 4.73
  • 52 Week Low
  • IMCR $23.15
  • TSLX $18.58
  • 52 Week High
  • IMCR $41.54
  • TSLX $24.42
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 51.47
  • TSLX 71.44
  • Support Level
  • IMCR $30.76
  • TSLX $23.67
  • Resistance Level
  • IMCR $33.95
  • TSLX $23.98
  • Average True Range (ATR)
  • IMCR 1.39
  • TSLX 0.39
  • MACD
  • IMCR -0.15
  • TSLX 0.06
  • Stochastic Oscillator
  • IMCR 43.05
  • TSLX 97.46

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: